Clinical trials: Child Allergy
Asthma, Perennial Allergic Rhinitis
Biomarkers of Cockroach Sublingual Immunotherapy 2
This trial is a follow-up study of the ICAC-12 Phase I/II trial (NCT00829985), and is designed to study biomarkers of the immune response to allergen immunotherapy and the safety of this therapy in a pediatric population.
- Trial name
- BioCSI-2 (NCT01380327)
- Testing
- Cockroach Sublingual Immunotherapy (SLIT) - Low Dose, Cockroach Sublingual Immunotherapy (SLIT) - High Dose
- Where
- 5 sites in United States
- Volunteers
- 99 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Food Hypersensitivity
A Study of Sublingual Immunotherapy in Peanut-allergic Children
The specific aim of this study is to determine if peanut allergen-specific SLIT will cause clinical desensitization and tolerance to develop in peanut-allergic young children.
- Trial name
- SLB (NCT00597727)
- Testing
- Peanut SLIT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of North Carolina, Chapel Hill
Eosinophilic Esophagitis, Milk Allergy
Milk Patch for Eosinophilic Esophagitis
This is a single-site, double-blind, placebo-controlled, randomized trial to study efficacy and safety of the Viaskin® Milk Patch for children with milk induced Eosinophilic Esophagitis (EoE).
- Trial name
- SMILEE (NCT02579876)
- Testing
- Viaskin Milk 500 mcg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Philadelphia
Asthma, Allergic Rhinitis
Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)
The purpose of this study is to assess real-world effectiveness of montelukast in children (2 to 14 years) with asthma and allergic rhinitis.
- Trial name
- NCT00442559
- Testing
- montelukast sodium, inhaled corticosteroid
- Volunteers
- 191 people
- Sponsor
- Organon and Co
Asthma
A Study of 2 Doses of MAP0010 in Asthmatic Children
The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.
- Trial name
- NCT00697697
- Testing
- 0.135mg MAP0010, 0.25mg MAP0010
- Volunteers
- 192 people
- Sponsor
- Allergan
Peanut Allergy
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
- Trial name
- NCT03292484
- Testing
- AR101
- Where
- 93 sites in United States, Canada and 8 more
- Volunteers
- 911 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
The objectives of this open-label follow-up study for subjects who previously were randomized and have completed the VIPES study for the treatment of peanut allergy, are: To assess the efficacy of Viaskin Peanut after up to 36…
- Trial name
- OLFUS-VIPES (NCT01955109)
- Testing
- Viaskin Peanut 250 mcg
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 171 people
- Sponsor
- DBV Technologies
Allergic Rhinitis, Chronic Urticaria
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.
- Trial name
- BALL (NCT00628108)
- Testing
- Levocetirizine 1.25 mg
- Where
- 26 sites in United States
- Volunteers
- 69 people
- Sponsor
- UCB Pharma
Peanut Allergy, Multi-food Allergy
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew…
- Trial name
- OUtMATCH (NCT03881696)
- Testing
- Omalizumab, Multi-Allergen Oral Immunotherapy
- Where
- 10 sites in United States
- Volunteers
- 458 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Eosinophilic Esophagitis (EoE)
Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
This is a randomized, placebo-controlled, parallel-arm, dose-ranging study in subjects with eosinophilic esophagitis, 2-18 years of age. Eligible subjects will be randomized into one of four treatment groups.
- Trial name
- NCT00762073
- Testing
- budesonide
- Where
- 20 sites in United States
- Volunteers
- 82 people
- Sponsor
- Shire
Asthma
A Dose-ranging Study of Fluticasone Furoate (FF)
This is a Phase IIb, multi-centre, stratified, randomised, double-blind, double-dummy, parallel-group, placebo and active controlled study in children aged 5-11 years with persistent uncontrolled asthma.
- Trial name
- NCT01563029
- Testing
- Fluticasone Furoate, Fluticasone Propionate
- Where
- 139 sites in United States, Bulgaria and 13 more
- Volunteers
- 597 people
- Sponsor
- GlaxoSmithKline
Severe Uncontrolled Asthma
PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma
This study will evaluate the PK, PD and long-term safety of Benralizumab administered subcutaneously in 30 children aged 6 to 11 years with severe eosinophilic asthma.
- Trial name
- TATE (NCT04305405)
- Testing
- Benralizumab
- Where
- 15 sites in United States, Japan
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Peanut Allergy
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT™) regimen in peanut-allergic children.
- Trial name
- RAMSES (NCT03126227)
- Testing
- AR101
- Where
- 67 sites in United States, Canada
- Volunteers
- 506 people
- Sponsor
- Aimmune Therapeutics, Inc.
Asthma
Timely Intravenous Magnesium for Asthma in Children
Many children currently being hospitalized with severe asthma could potentially avoid hospitalization and be sent home if their treatment in the emergency department was more effective.
- Trial name
- IMPACT-ED (NCT05166811)
- Testing
- Magnesium Sulfate, Heptahydrate, 0.9% saline
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Utah
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.
- Trial name
- NCT01700192
- Testing
- MK-8237 tablets, Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets
- Volunteers
- 1,482 people
- Sponsor
- ALK-Abelló A/S
Asthma in Children
Effectiveness of Telemedicine Home Assessments for Identification and Reduction of Asthma Triggers
The study is about comparing asthma home assessments/interventions by telemedicine compared to providing education alone. Interactive Video (IAV) defines telemedicine.
- Trial name
- NCT04896502
- Testing
- Standard of Care Education, Interactive Video (IAV) Telemedicine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Arkansas
Nasal Congestion, Respiratory Tract Infection
Home Usability of a Nasal Lavage System in Children
This study evaluates labeling comprehension, ease of use and effectiveness of a new device for nasal and sinus irrigation and/or aspiration. The device is currently cleared for professional use and home use with a prescription.
- Conditions
- Nasal Congestion, Respiratory Tract Infection, Sinusitis, Allergic Rhinitis
- Trial name
- NCT01129765
- Testing
- Use of an automatic nasal irrigator/aspirator
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aardvark Medical Company
Food Allergy
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
- Trial name
- NCT04856865
- Testing
- Low dose ADP101, High dose ADP101
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Peanut Allergy
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
The objectives of this dose-finding study for the treatment of peanut allergy are: To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize…
- Trial name
- VIPES (NCT01675882)
- Testing
- Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- DBV Technologies
Atopic Dermatitis
5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical…
- Trial name
- NCT00120523
- Testing
- Pimecrolimus, Topical corticosteroids
- Where
- 31 sites in United States, Germany
- Volunteers
- 2,418 people
- Sponsor
- MEDA Pharma GmbH & Co. KG